• In June 2026, Indivior Pharmaceuticals, Inc. was added to multiple Russell 2000 indices, including the Growth-Defensive, Defensive, and Value-Defensive sub-indices, highlighting its evolving profile within the small-cap universe.
• This cluster of index inclusions can increase Indivior’s visibility with institutional investors and passive funds that track Russell 2000 segments, potentially reshaping how the company is positioned in portfolios focused on defensive characteristics.
• We’ll now examine how Indivior’s addition to multiple Russell 2000 defensive indices may influence the company’s opioid treatment-focused investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior, you need to believe in the long acting injectable model for opioid use disorder and the company’s ability to translate SUBLOCADE adoption and cost discipline into durable earnings and cash generation. The key near term catalyst remains execution on SUBLOCADE growth and margin improvement, while concentration in a single product category and negative equity are important risks. The new Russell 2000 defensive index inclusions do not materially change those fundamentals in the short term.

Among recent announcements, the most relevant to this index inclusion is Indivior’s decision to raise its 2026 net revenue guidance to US$1,215 million to US$1,285 million. That higher outlook, combined with share repurchases, frames why some investors may now see Indivior as fitting “defensive” small cap profiles, with the guidance range and capital returns both feeding directly into how investors assess near term earnings power and portfolio fit.

Yet behind the defensive label, investors should be aware that Indivior’s heavy dependence on SUBLOCADE and the long acting injectable category could...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and a roughly $353.5 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, a 9% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$1.5 billion in revenue and roughly US$589 million in earnings by 2029, which paints a far more upbeat picture than consensus. In light of Indivior’s new Russell 2000 defensive index status and the risk that long acting injectable adoption might lag those bullish hopes, it is worth recognizing how far apart these views can be and considering how both narratives could shift as new data comes through.

Explore 5 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth 23% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.